← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Synedgen, Inc.
Claremont, CA
$17,787,418
Total funding
11
Grants
Funding over time
peak $9.1M · FY2008–22$10M$7.5M$5M$2.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
DOD$13,828,228 · 3
NIH$3,959,190 · 8
By mechanism
—$13,828,228 · 3
R44$1,963,826 · 1
U01$1,078,629 · 1
R43$720,028 · 5
N43$196,707 · 1
Investigators at Synedgen, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
PROCESS DEVELOPMENT AND CHEMICAL MODIFICATION OF MEDICAL GRADE CHITOSAN$9,122,646
· FY2008 · Department of Defense
OPTIMIZED GLYCOPOLYMER-MIMICKING POLYSACCHARIDE TO PROVIDE BARRIER FUNCTION AND RESTORE GASTROINTESTINAL INTEGRITY AND HOMEOSTASIS IN INFLAMMATORY BOWEL DISEASES$4,445,860
· FY2022 · Defense Health Agency
Antimicrobial and Regenerative Treatment for Oral Mucositis$992,846
R44 · FY2011 · DE
Antimicrobial and Regenerative Treatment for Oral Mucositis$970,980
R44 · FY2012 · DE
Identification of lead compounds to topically treat sulfur mustard injury to reduce ocular damage and improve vision.$329,155
U01 · FY2019 · EY
Identification of lead compounds to topically treat sulfur mustard injury to reduce ocular damage and improve vision.$321,965
U01 · FY2020 · EY
Identification of lead compounds to topically treat sulfur mustard injury to reduce ocular damage and improve vision.$319,250
U01 · FY2021 · EY
GLYCOPOLYMER-MIMICKING POLYSACCHARIDES TO PROVIDE BARRIER FUNCTION AND RESTORE GASTROINTESTINAL INTEGRITY AND HOMEOSTASIS IN INFLAMMATORY BOWEL DISEA$259,723
· FY2019 · Defense Health Agency
Novel treatment for Crohn's disease and related inflammatory gastrointestinal disease$224,412
R43 · FY2016 · DK
Novel Topical Radioprotector for Gl Mucosal Exposure$196,707
N43 · FY2014 · CA
Mucolytic for enhanced mucus and biofilm clearance in cystic fibrosis patients$149,901
R43 · FY2013 · HL
Prevention and treatment of GI obstruction syndromes in cystic fibrosis$146,412
R43 · FY2015 · DK
Prevention and Treatment of Oral Biofilms and Related Oral Disease by Soluble Chi$99,665
R43 · FY2009 · DE
Wound Decontamination for the Prevention and Treatment of Multi-drug Resistant Ba$99,638
R43 · FY2010 · AI
Identification of lead compounds to topically treat sulfur mustard injury to reduce ocular damage and improve vision.$74,526
U01 · FY2020 · EY
Identification of lead compounds to topically treat sulfur mustard injury to reduce ocular damage and improve vision.$33,733
U01 · FY2022 · EY